Astellas Pharma Gmbh

Ganymed Pharmaceuticals Ag

Biontech Ag

Tron—translationale Onkologie an Der Universitátsmedizin Der Johannes Gutenberg—universität Mainz Gemeinnützige Gmbh

Biontech Se

Universitätsmedizin Der Johannes Gutenberg-Universitat Mainz

Tron-Translationale Onkologie an Der Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz

Ganymed Pharmaceuticals Gmbh

Tron Ggmbh

Tron—translationale Onkologie an Der Universitatsmedizin Der Johannes Gutenberg-Universitat at Mainz Gemeinnutzige Gmbh

Tron—translationale Onkologic an Der Universitätsmedzin Der Johannes Gutenberg-Universität Mainz Gemcinnützige Gmbh

Tron - Translationale Onkologie an Der Universitatsmedizen Der Johannes Gutenberg-Universitat Mainz Gemeinnutzige Gmbh

Christiane Regina Stadler

Ugur Sahin

Ozlem Tureci

Rita Mitnacht-Kraus

Stefan Jacobs

Magdalena Jadwiga Utsch

Cornelia Adriana Maria Heinz

Fabrice Le Gall

Arne Jendretzki

Özlem Türeci

Markus Fiedler

Tim Beissert

Julia Holland

Hayat Bähr-Mahmud

Laura Plum

Maria Kreuzberg

Ozlem Türeci

Leyla Fischer

Stefan Denis Jacobs

Hayat Bahr-Mahmud

The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.

Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer

The present invention provides binding agents comprising at least three binding domains, wherein a first binding domain binds to a T cell-specific antigen and a second binding domain and a third binding domain bind to a claudin, and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.

Bispecific trivalent antibodies binding to Claudin6 or Claudin18.2 and CD3 for treatment of Claudin expressing cancer diseases

The present invention provides binding agents that contain n binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor-associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.

Agents for treatment of claudin expressing cancer diseases

The present invention provides binding agents that contain a binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor-associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.

Combination therapy involving antibodies against claudin 18.2 for treatment of cancer

Growing community of inventors

Bensheim, Germany

Christiane Regina Stadler